Founded by a team of food scientists, process engineers, and market developers with nearly a century of combined food industry experience, Quintessence Nutraceuticals brings together a consortium of experts with an intensely committed passion for improving global health and wellness on a holistic level.
It began with a desire to mitigate food insecurity and chronic malnutrition among children in developing countries. The team knew the solution needed to be sustainable and regionally applicable. Following nearly a decade of research and development, NutraIso® was born.
Using patented enzymatic hydrolyzation technology, Quintessence extracts the nutraceutical and pharmacological isolates from the bran and germ layers of rice. No longer rice, but a derivative thereof, plant-based NutraIso is an all-natural, highly bioavailable and bioactive nutraceutical ingredient producing measurable and life-changing results. These benefits are clinically proven to address health concerns across populations and life stages: from prenatal to pre-diabetic, infant to senior wellness.
An experienced and agile team of professionals, each expert in their roles—they seek to answer what is the greatest question of our time: “How do we make life-changing nutrition more accessible to nutritionally deficient populations worldwide?”
In partnering with global food and beverage companies, Quintessence Nutraceuticals is strategically focused on incorporating NutraIso into a range of consumer products and condition-specific foods, making a paradigm changing difference in enhancing health and wellness naturally.
Whom We Support
Sustainable Nutrition International
Changing the life of a child not just for a day but for a lifetime
Sustainable Nutrition International (SNI) is an independent 501c3 Charitable Organization registered in the United States and focused on delivering bioactive nutrition to nutrient-deficient populations. SNI’s primary mission is to remediate chronic malnutrition in children through early intervention with proprietary and clinically documented nutraceutical formulations for lactating mothers and their breastfed infants.
The documented capacity of NutraIso to remediate the physical and cognitive effects of chronic malnutrition among breastfed infants is at the heart of SNI’s program initiatives. Phase 1 early intervention field clinical trials in Central America demonstrated the significant impact NutraIso can have in undernourished populations. In 2013, the NutraIso technology received the Patents for Humanity Award for remediating chronic malnutrition in lactating mothers and their breastfed infants.
There are 165 million children under the age of 5 living in a state of chronic malnutrition. Between birth and 24 months of age, nutrition is critical for physical growth and cognitive ability, as well as building a strong immune system that supports persons through the adult years. Chronic malnutrition and inadequate dietary intake in infancy can lead to stunted growth and decreased mental development, leading to a lifetime of underachievement and socioeconomic struggle.
This perpetuation of poverty can have a multi-generational and whole-community impact long-term. Sustainable Nutrition International is working to provide life-changing nutritional intervention to these at-risk populations, and Quintessence Nutraceuticals is proud to be associated with that effort.
Learn more about Sustainable Nutrition International.
Glenn H. Sullivan, PhD
Dr. Glenn H. Sullivan is the Founding Partner of Quintessence Nutraceuticals. A globally respected agriculture and food scientist, Dr. Sullivan is known for his significant food technology achievements in the research and development of functional foods. His career spans more than 50 years addressing domestic and international issues related to global food security concerns across academic research, government agencies, and global business development sectors. He holds five patents for food processing technology including the first U.S. patent for a clinically documented all-natural nutraceutical to reduce insulin resistance in prediabetic and Type 2 diabetic individuals. He was awarded the 2013 Patents for Humanity for remediating chronic malnutrition in lactating mothers and their breastfed infants. He is Professor Emeritus with the Food Science Institute at Purdue University.
Michael A. Tarrasch is a capital management executive and the managing partner at Quintessence Nutraceuticals LLC. Previously, Michael served as Treasurer and Vice Chairman of the Board of Directors of Broadview Investments, the holding company for Pharma Tech Industries. He earned a Master of Business Administration from Washington University in St. Louis, an MS in Management Information Systems from the University of Missouri–St. Louis, and a Bachelor of Science in Finance from Missouri State University.
Director of Science and Compliance
Laura Tagliani is the Director of Science and Compliance at Quintessence Nutraceuticals LLC. With a BS in Agriculture from the University of California, Davis, and an MS in Plant Breeding and Genetics from Montana State University, Laura brings 35 years extensive experience in plant science and biotechnology with emphasis on regulatory affairs and program management. As a Research Fellow with Dow AgroSciences, she successfully led strategic programs in new product development, regulatory compliance, and new product launches. Laura has overall responsibility for quality, compliance, and technical aspects of plant-based nutraceutical product development with Quintessence.
Get in touch to learn more about Quintessence Nutraceuticals and our paradigm-changing nutraceutical, NutraIso.